Bicycle Therapeutics (BCYC) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Bicycle Therapeutics faces a significant business risk due to the concentrated ownership of its shares, primarily held by the Baker Entities, which own approximately 19.9% of the ordinary shares. This concentration, combined with the influence of certain executive officers and directors, means that around 37% of the voting power is controlled by a small group. This could lead to corporate decisions that may not align with the broader interests of other shareholders, potentially affecting the company’s strategic direction and its market valuation. The substantial influence of these shareholders may also discourage potential acquisitions or business combinations, impacting the attractiveness of Bicycle Therapeutics to potential investors.
The average BCYC stock price target is $39.40, implying 68.05% upside potential.
To learn more about Bicycle Therapeutics’ risk factors, click here.
